These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
316 related items for PubMed ID: 2587673
1. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice]. Da Prada M, Keller HH, Kettler R. Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673 [Abstract] [Full Text] [Related]
2. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine. Lavian G, Finberg JP, Youdim MB. Clin Neuropharmacol; 1993 Aug; 16 Suppl 2():S1-7. PubMed ID: 8313392 [Abstract] [Full Text] [Related]
3. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. Da Prada M, Kettler R, Keller HH, Burkard WP, Haefely WE. J Neural Transm Suppl; 1989 Aug; 28():5-20. PubMed ID: 2677242 [Abstract] [Full Text] [Related]
4. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin. Kato M, Katayama T, Iwata H, Yamamura M, Matsuoka Y, Narita H. J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858 [Abstract] [Full Text] [Related]
5. Pre-clinical pharmacology of moclobemide. A review of published studies. Burkard WP, Da Prada M, Keller HH, Kettler R, Haefely W. Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131 [Abstract] [Full Text] [Related]
6. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. Caille D, Bergis OE, Fankhauser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, Jarreau FX. J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929 [Abstract] [Full Text] [Related]
7. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats. Da Prada M, Burkard WP. Acta Psychiatr Scand Suppl; 1990 Apr; 360():106-7. PubMed ID: 2248060 [Abstract] [Full Text] [Related]
8. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies]. Bieck PR. Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674 [Abstract] [Full Text] [Related]
9. [The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine]. Andreeva NI, Golovina SM, Faermark MF, Shvarts GIa, Mashkovskiĭ MD. Farmakol Toksikol; 1991 Aug; 54(2):38-40. PubMed ID: 1884793 [Abstract] [Full Text] [Related]
10. Some basic aspects of reversible inhibitors of monoamine oxidase-A. Da Prada M, Kettler R, Burkard WP, Lorez HP, Haefely W. Acta Psychiatr Scand Suppl; 1990 Aug; 360():7-12. PubMed ID: 2248079 [Abstract] [Full Text] [Related]
11. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. Colzi A, D'Agostini F, Cesura AM, Borroni E, Da Prada M. J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998 [Abstract] [Full Text] [Related]
12. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RK, Wyss PC. J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284 [Abstract] [Full Text] [Related]
13. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors. Zimmer R. Acta Psychiatr Scand Suppl; 1990 Jan; 360():81-3. PubMed ID: 2248084 [Abstract] [Full Text] [Related]
14. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Kettler R, Da Prada M, Burkard WP. Acta Psychiatr Scand Suppl; 1990 Jan; 360():101-2. PubMed ID: 2248058 [Abstract] [Full Text] [Related]
15. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Youdim MB, Weinstock M. Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899 [Abstract] [Full Text] [Related]
16. Tranylcypromine, but not moclobemide, prolongs the inhibitory action of dopamine on midbrain dopaminergic neurons: an in vitro electrophysiological study. Mercuri NB, Federici M, Marinelli S, Bernardi G. Synapse; 2000 Sep 01; 37(3):216-21. PubMed ID: 10881043 [Abstract] [Full Text] [Related]
17. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings. Möller HJ, Wendt G, Waldmeier P. Pharmacopsychiatry; 1991 Mar 01; 24(2):50-4. PubMed ID: 1852792 [Abstract] [Full Text] [Related]
18. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects. Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ. Psychopharmacology (Berl); 1992 Mar 01; 106 Suppl():S68-70. PubMed ID: 1546145 [Abstract] [Full Text] [Related]
19. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors. Alemany R, Olmos G, García-Sevilla JA. Br J Pharmacol; 1995 Feb 01; 114(4):837-45. PubMed ID: 7773544 [Abstract] [Full Text] [Related]
20. The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats. Zajaczkowski W, Górka Z. Pol J Pharmacol; 1993 Feb 01; 45(2):157-66. PubMed ID: 8401768 [Abstract] [Full Text] [Related] Page: [Next] [New Search]